Provectus Biopharmaceuticals Valuation
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceutica seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Provectus Biopharmaceutica from analyzing the company fundamentals such as Shares Owned By Institutions of 0.04 %, return on asset of -1.85, and Shares Outstanding of 419.55 M as well as examining its technical indicators and probability of bankruptcy. . In general, most investors support acquiring undervalued entities and selling overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Provectus Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Provectus Biopharmaceutica is based on 3 months time horizon. Increasing Provectus Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Provectus otc stock is determined by what a typical buyer is willing to pay for full or partial control of Provectus Biopharmaceuticals. Since Provectus Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Provectus OTC Stock. However, Provectus Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.11 | Real 0.0999 | Hype 0.11 | Naive 0.0942 |
The intrinsic value of Provectus Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Provectus Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Provectus Biopharmaceuticals helps investors to forecast how Provectus otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Provectus Biopharmaceutica more accurately as focusing exclusively on Provectus Biopharmaceutica's fundamentals will not take into account other important factors: Provectus Biopharmaceutica Total Value Analysis
Provectus Biopharmaceuticals is at this time forecasted to have valuation of 46.73 M with market capitalization of 44.47 M, debt of 2.29 M, and cash on hands of 84.27 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Provectus Biopharmaceutica fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
46.73 M | 44.47 M | 2.29 M | 84.27 K |
Provectus Biopharmaceutica Asset Utilization
One of the ways to look at asset utilization of Provectus is to check how much profit was generated for every dollar of assets it reports. Provectus Biopharmaceutica holds a negative application of assets of -1.85 pct., losing $0.0185 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Provectus Biopharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Provectus Biopharmaceutica Ownership Allocation
Provectus Biopharmaceutica owns a total of 419.55 Million outstanding shares. Provectus Biopharmaceutica holds 3.69 pct. of its outstanding shares held by insiders and 0.04 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Provectus Biopharmaceutica Profitability Analysis
Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0.About Provectus Biopharmaceutica Valuation
The otc valuation mechanism determines Provectus Biopharmaceutica's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Provectus Biopharmaceutica based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Provectus Biopharmaceutica. We calculate exposure to Provectus Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Provectus Biopharmaceutica's related companies.Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
8 Steps to conduct Provectus Biopharmaceutica's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Provectus Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Provectus Biopharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Provectus Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Provectus Biopharmaceutica's revenue streams: Identify Provectus Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Provectus Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Provectus Biopharmaceutica's growth potential: Evaluate Provectus Biopharmaceutica's management, business model, and growth potential.
- Determine Provectus Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Provectus Biopharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Provectus Biopharmaceutica Growth Indicators
Investing in growth stocks can be very risky. If the company such as Provectus Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 419.4 M | |
| Retained Earnings | -246 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |